乳腺癌是女性最常见的癌症,终生患病率约为12%,我国每年发病人数约为30.4万,其中女性精神分裂症患者中的乳腺癌患者比普通人群更常见。现如今药物依旧为精神科的最常用治疗手段,但目前尚不清楚精神科常用药物与乳腺癌发病风险之间的关系。所以笔者此次对这方面的研究进展进行综述,以便更好地指导临床用药,为进一步研究提供新方向。
Breast cancer is the most common cancer in women, with a lifetime prevalence rate of about 12%. The number of cases in China is about 304,000 every year, among which breast cancer patients with female schizophrenia are more common than the general population. Nowadays, drugs are still the most commonly used treatment in psychiatry, but the relationship between commonly used psy-chiatric drugs and the risk of breast cancer is not clear. Therefore, the author summarizes the re-search progress in this area, in order to better guide the clinical use of drugs and provide a new di-rection for further research.
催乳素,高催乳素血症,抗精神病药物,乳腺癌, Prolactin Hyperprolactinemia Antipsychotics Breast Cancer摘要
2Department of Psychiatry, Shandong Mental Health Center, Shandong University, Jinan Shandong
3Department of Psychiatry, Yiyuan County Mental Health Center, Zibo Shandong
Received: Apr. 18th, 2022; accepted: May 12th, 2022; published: May 19th, 2022
ABSTRACT
Breast cancer is the most common cancer in women, with a lifetime prevalence rate of about 12%. The number of cases in China is about 304,000 every year, among which breast cancer patients with female schizophrenia are more common than the general population. Nowadays, drugs are still the most commonly used treatment in psychiatry, but the relationship between commonly used psychiatric drugs and the risk of breast cancer is not clear. Therefore, the author summarizes the research progress in this area, in order to better guide the clinical use of drugs and provide a new direction for further research.
Keywords:Prolactin, Hyperprolactinemia, Antipsychotics, Breast Cancer
王忠宝,马家树,王 倩,刘 鹏,李然然. 精神科常用药物与乳腺癌发病风险的研究进展Research Progress on the Relationship between Commonly Used Drugs in Psychiatry and the Risk of Breast Cancer[J]. 临床医学进展, 2022, 12(05): 4221-4227. https://doi.org/10.12677/ACM.2022.125611
参考文献ReferencesRojas, K. and Stuckey, A. (2016) Breast Cancer Epidemiology and Risk Factors. Clinical Obstetrics and Gynecology, 59, 651-672. <br>https://doi.org/10.1097/GRF.0000000000000239中国神经科学学会精神病学基础与临床分会精神分裂症临床研究联盟. 抗精神病药所致高泌乳素血症干预对策的专家共识[J]. 中华精神科杂志, 2021, 54(3): 163-169.Clevenger, C.V., Furth, P.A., Hankinson, S.E., et al. (2003) The Role of Prolactin in Mammary Carci-noma. Endocrine Reviews, 24, 1-27. <br>https://doi.org/10.1210/er.2001-0036Rahman, T., Clevenger, C.V., Kaklamani, V., et al. (2014) Antipsychotic Treatment in Breast Cancer Patients. The American Journal of Psychiatry, 171, 616-621. <br>https://doi.org/10.1176/appi.ajp.2013.13050650Cookson, J., Hodgson, R. and Wildgust, H.J. (2012) Prolactin, Hyperprolactinaemia and Antipsychotic Treatment: A Review and Lessons for Treatment of Early Psychosis. Journal of Psychopharmacology, 26, 42-51.
<br>https://doi.org/10.1177/0269881112442016Clevenger, C.V., Chang, W.P., Ngo, W., et al. (1995) Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma. Evidence for an Autocrine/Paracrine Loop. The Ameri-can Journal of Pathology, 146, 695-705.Samperi, I., Lithgow, K. and Karavitaki, N. (2019) Hyperprolactinaemia. Journal of Clinical Medicine, 8, 2203.
<br>https://doi.org/10.3390/jcm8122203Tikk, K., Sookthai, D., Fortner, R.T., et al. (2015) Circulating Prolactin and in Situ Breast Cancer Risk in the European EPIC Cohort: A Case-Control Study. Breast Cancer Research, 17, 49. <br>https://doi.org/10.1186/s13058-015-0563-6Tikk, K., Sookthai, D., Johnson, T., et al. (2014) Circulating Pro-lactin and Breast Cancer Risk among Pre- and Postmenopausal Women in the EPIC Cohort. Annals of Oncology, 25, 1422-1428. <br>https://doi.org/10.1093/annonc/mdu150Gupta, N., Mendiratta, G., Singal, R., et al. (2017) Plasma Prolactin and Total Lipid Levels and Subsequent Risk of Breast Cancer in Pre- and Postmenopausal Women: Experience from an Indian Rural Centre. Maedica (Bucur), 12, 258-266.Gabrielson, M., Ubhayasekera, K., Ek, B., et al. (2018) Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. JNCI Cancer Spectrum, 2, pky055.
<br>https://doi.org/10.1093/jncics/pky055Lissoni, P., Barni, S., Cazzaniga, M., et al. (1995) Prediction of Recur-rence in Operable Breast Cancer by Postoperative Changes in Prolactin Secretion. Oncology, 52, 439-442. <br>https://doi.org/10.1159/000227507Wang, D.Y., Stepniewska, K.A., Allen, D.S., et al. (1995) Serum Prolactin Levels and Their Relationship to Survival in Women with Operable Breast Cancer. Journal of Clinical Epidemiology, 48, 959-968.
<br>https://doi.org/10.1016/0895-4356(94)00201-ZBazan, J.F. (1990) Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily. Proceedings of the National Academy of Sciences of the United States of America, 87, 6934-6938. <br>https://doi.org/10.1073/pnas.87.18.6934Reynolds, C., Montone, K.T., Powell, C.M., et al. (1997) Expression of Prolactin and Its Receptor in Human Breast Carcinoma. Endocrinology, 138, 5555-5560. <br>https://doi.org/10.1210/endo.138.12.5605O’Leary, K.A., Rugowski, D.E., Shea, M.P., et al. (2021) Prolactin Synergizes with Canonical Wnt Signals to Drive Development of ER+ Mammary Tumors via Activation of the Notch Pathway. Cancer Letters, 503, 231-239.
<br>https://doi.org/10.1016/j.canlet.2021.01.012Thomas, L.N., Chedrawe, E.R., Barnes, P.J., et al. (2017) Prolac-tin/Androgen-Inducible Carboxypeptidase-D Increases with Nitrotyrosine and Ki67 for Breast Cancer Progression in Vi-vo, and Upregulates Progression Markers VEGF-C and Runx2 in Vitro. Breast Cancer Research and Treatment, 164, 27-40. <br>https://doi.org/10.1007/s10549-017-4223-7Fiorillo, A.A., Medler, T., Feeney, Y.B., et al. (2013) The Prolactin Receptor Transactivation Domain Is Associated with Steroid Hormone Receptor Expression and Malignant Progression of Breast Cancer. The American Journal of Pathology, 182, 217-233. <br>https://doi.org/10.1016/j.ajpath.2012.09.021Campbell, G.S., Argetsinger, L.S., Ihle, J.N., et al. (1994) Acti-vation of JAK2 Tyrosine Kinase by Prolactin Receptors in Nb2 Cells and Mouse Mammary Gland Explants. Proceedings of the National Academy of Sciences of the United States of America, 91, 5232-5236. <br>https://doi.org/10.1073/pnas.91.12.5232Clevenger, C.V. and Medaglia, M.V. (1994) The Protein Tyrosine Kinase P59fyn Is Associated with Prolactin (PRL) Receptor and Is Activated by PRL Stimulation of T-Lymphocytes. Molecular Endocrinology, 8, 674-681.
<br>https://doi.org/10.1210/mend.8.6.7935483Clevenger, C.V., Torigoe, T. and Reed, J.C. (1994) Prolactin In-duces Rapid Phosphorylation and Activation of Prolactin Receptor-Associated RAF-1 Kinase in a T-Cell Line. Journal of Biological Chemistry, 269, 5559.
<br>https://doi.org/10.1016/S0021-9258(17)37498-7Clevenger, C.V., Ngo, W., Sokol, D.L., et al. (1995) Vav Is Necessary for Prolactin-Stimulated Proliferation and Is Translocated into the Nucleus of a T-Cell Line. Journal of Bio-logical Chemistry, 270, 13246-13253.
<br>https://doi.org/10.1074/jbc.270.22.13246Kline, J.B., Roehrs, H. and Clevenger, C.V. (1999) Functional Characterization of the Intermediate Isoform of the Human Prolactin Receptor. Journal of Biological Chemistry, 274, 35461-35468.
<br>https://doi.org/10.1074/jbc.274.50.35461Horseman, N.D. (2001) [Endocrine Updates] Prolactin Volume 12. Prolactin Receptor Signal Transduction. Chapter 18, Springer, Berlin, 355-379. <br>https://doi.org/10.1007/978-1-4615-1683-5_18DaSilva, L., Rui, H., Erwin, R.A., et al. (1996) Prolactin Re-cruits STAT1, STAT3 and STAT5 Independent of Conserved Receptor Tyrosines TYR402, TYR479, TYR515 and TYR580. Molecular and Cellular Endocrinology, 117, 131-140. <br>https://doi.org/10.1016/0303-7207(95)03738-1Clevenger, C.V. (2004) Roles and Regulation of Stat Family Transcription Factors in Human Breast Cancer. The American Journal of Pathology, 165, 1449-1460. <br>https://doi.org/10.1016/S0002-9440(10)63403-7Fiorillo, A.A., Medler, T.R., Feeney, Y.B., et al. (2011) HMGN2 Inducibly Binds a Novel Transactivation Domain in Nuclear PRLr to Coordinate Stat5a-Mediated Transcription. Molecular Endocrinology, 25, 1550-1564.
<br>https://doi.org/10.1210/me.2011-0106Wennbo, H., Gebre-Medhin, M., Gritli-Linde, A., et al. (1997) Activa-tion of the Prolactin Receptor But Not the Growth Hormone Receptor Is Important for Induction of Mammary Tumors in Transgenic mice. Journal of Clinical Investigation, 100, 2744-2751. <br>https://doi.org/10.1172/JCI119820Dwivedi, A., Padala, C., Kumari, A., et al. (2021) Hematopoietic PBX-Interacting Protein Is a Novel Regulator of Mammary Epithelial Cell Differentiation. The FEBS Journal, 289, 1575-1590. <br>https://doi.org/10.1111/febs.16242Chen, Z., Luo, J., Zhang, C., et al. (2018) Mechanism of Pro-lactin Inhibition of miR-135b via Methylation in Goat Mammary Epithelial Cells. Journal of Cellular Physiology, 233, 651-662. <br>https://doi.org/10.1002/jcp.25925Hua, K., Jin, J., Zhao, J., et al. (2016) miR-135b, Upregulated in Breast Cancer, Promotes Cell Growth and Disrupts the Cell Cycle by Regulating LATS2. International Journal of On-cology, 48, 1997-2006.
<br>https://doi.org/10.3892/ijo.2016.3405Wang, P.S., Walker, A.M., Tsuang, M.T., et al. (2002) Dopamine An-tagonists and the Development of Breast Cancer. Archives of General Psychiatry, 59, 1147-1154. <br>https://doi.org/10.1001/archpsyc.59.12.1147Yang, L., Yao, Y., Yong, L., et al. (2019) Dopamine D(1) Re-ceptor Agonists Inhibit Lung Metastasis of Breast Cancer Reducing Cancer Stemness. European Journal of Pharmacol-ogy, 859, Article ID: 172499.
<br>https://doi.org/10.1016/j.ejphar.2019.172499Ji, J., Sundquist, K., Ning, Y., et al. (2013) Incidence of Cancer in Patients with Schizophrenia and Their First-Degree Relatives: A Population-Based Study in Sweden. Schizophrenia Bulletin, 39, 527-536.
<br>https://doi.org/10.1093/schbul/sbs065Wu, C., Wang, Y.C., Lin, C.L., et al. (2017) Female Schizophrenia Pa-tients and Risk of Breast Cancer: A Population-Based Cohort Study. Schizophrenia Research, 188, 165-171. <br>https://doi.org/10.1016/j.schres.2017.01.019Rahman, T., Sahrmann, J.M., Olsen, M.A., et al. (2022) Risk of Breast Cancer with Prolactin Elevating Antipsychotic Drugs: An Observational Study of US Women (Ages 18-64 Years). Journal of Clinical Psychopharmacology, 42, 7-16.
<br>https://doi.org/10.1097/JCP.0000000000001513Taipale, H., Solmi, M., Lähteenvuo, M., et al. (2021) Anti-psychotic Use and Risk of Breast Cancer in Women with Schizophrenia: A Nationwide Nested Case-Control Study in Finland. The Lancet Psychiatry, 8, 883-891.
<br>https://doi.org/10.1016/S2215-0366(21)00241-8Andrade, C. (2021) Understanding the Limitations of the Odds Ratio in a Case-Control Study of the Association between Breast Cancer and Exposure to Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 82, 21f14319.
<br>https://doi.org/10.4088/JCP.21f14319Johnston, A.N., Bu, W., Hein, S., et al. (2018) Hyperprolac-tinemia-Inducing Antipsychotics Increase Breast Cancer Risk by Activating JAK-STAT5 in Precancerous Lesions. Breast Cancer Research, 20, 42.
<br>https://doi.org/10.1186/s13058-018-0969-zHaukka, J., Sankila, R., Klaukka, T., et al. (2010) Incidence of Cancer and Antidepressant Medication: Record Linkage Study. International Journal of Cancer, 126, 285-296. <br>https://doi.org/10.1002/ijc.24537Reeves, K.W., Okereke, O.I., Qian, J., et al. (2018) Depression, Antidepres-sant Use, and Breast Cancer Risk in Pre- and Postmenopausal Women: A Prospective Cohort Study. Cancer Epidemiol-ogy, Biomarkers & Prevention, 27, 306-314.
<br>https://doi.org/10.1158/1055-9965.EPI-17-0707Chen, V.C., Liao, Y.T., Yeh, D.C., et al. (2016) Relationship between Antidepressant Prescription and Breast Cancer: A Population Based Study in Taiwan. Psychooncology, 25, 803-807. <br>https://doi.org/10.1002/pon.3929Busby, J., Mills, K., Zhang, S.D., et al. (2018) Selective Serotonin Reuptake Inhibitor Use and Breast Cancer Survival: A Population-Based Cohort Study. Breast Cancer Research, 20, 4. <br>https://doi.org/10.1186/s13058-017-0928-0